{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:40:11Z","timestamp":1750005611018,"version":"3.41.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">Neisseria meningitidis<\/jats:italic> serogroup B (MenB) causes most meningitis outbreaks worldwide. We evaluated the ability of the 4-component MenB vaccine (4CMenB) to induce bactericidal activity against outbreak strains in adolescents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Individual sera from 20 United States and 23 Chilean adolescents who received 2 doses of 4CMenB 2 months apart were assayed at prevaccination and 1 month after second dose using a human complement serum bactericidal antibody assay (hSBA) against a full or subset strain panel consisting of 14 MenB outbreak strains and 1 MenW hyperendemic strain collected between 2001 and 2017 in the United States, United Kingdom, and France. Bactericidal activity was determined as the percentage of adolescents with hSBA titer \u22651:4 or \u22651:8.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>One month after the second 4CMenB dose, antibodies from 65% to 100% of the US adolescents were able to kill 12 of 15 strains at 1:4 dilution. The remaining 3 strains were killed by 45%, 25%, and 15% of US adolescent sera. Similar percentages exhibited hSBA titers of \u22651:8. Across a subset of 4 strains, point estimates for the percentages of Chilean and US adolescents with hSBA titers of \u22651:4 after the second 4CMenB dose were similar (100% for strain M27703, 74% vs. 80% for M26312, 52% vs. 45% for M08 0240745), except for strain M39090 (91% vs. 65%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study was the first to evaluate bactericidal activity elicited by a MenB vaccine against 15 outbreak strains. Two doses of 4CMenB elicited bactericidal activity against MenB outbreak strains and a hyperendemic MenW strain.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002957","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T20:56:31Z","timestamp":1602795391000},"page":"e66-e71","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents"],"prefix":"10.1097","volume":"40","author":[{"given":"Alessia","family":"Biolchi","sequence":"first","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Tomei","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Santini","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"La Gaetana","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mori","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Novy","sequence":"additional","affiliation":[{"name":"GSK, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafik","family":"Bekkat-Berkani","sequence":"additional","affiliation":[{"name":"GSK, Rockville, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia Monica","family":"Giuliani","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[{"name":"GSK, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"2 suppl","key":"R2-20250615","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements.","volume":"59","author":"Martin\u00f3n-Torres","year":"2016","journal-title":"J Adolesc Health"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1586\/14760584.2015.1004317","article-title":"Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives.","volume":"14","author":"Whelan","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3201\/eid0808.010422","article-title":"Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.","volume":"8","author":"Aguilera","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.vaccine.2016.02.014","article-title":"Global epidemiology of capsular group W meningococcal disease (1970-2015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex.","volume":"34","author":"Mustapha","year":"2016","journal-title":"Vaccine"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"1800245","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800245","article-title":"Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017.","volume":"24","author":"Krone","year":"2019","journal-title":"Euro Surveill"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004-2014.","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fimmu.2019.00751","article-title":"The development of a vaccine against meningococcus B using reverse vaccinology.","volume":"10","author":"Masignani","year":"2019","journal-title":"Front Immunol"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines.","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada.","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11908-017-0587-4","article-title":"Serogroup B meningococcus outbreaks, prevalence, and the case for standard vaccination.","volume":"19","author":"Grogan","year":"2017","journal-title":"Curr Infect Dis Rep"},{"key":"R16-20250615","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/21645515.2018.1458175","article-title":"Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.","volume":"14","author":"Villena","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1514866","article-title":"Immunogenicity of a meningococcal B vaccine during a University Outbreak.","volume":"375","author":"Basta","year":"2016","journal-title":"N Engl J Med"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1514866","article-title":"Meningococcal B vaccine during a university outbreak.","volume":"375","author":"Basta","year":"2016","journal-title":"N Engl J Med"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3201\/eid2503.181574","article-title":"University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013-2018.","volume":"25","author":"Soeters","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/cid\/cix519","article-title":"Serum bactericidal antibody responses of students immunized with a meningococcal serogroup B vaccine in response to an outbreak on a university campus.","volume":"65","author":"Lujan","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.vaccine.2017.01.066","article-title":"Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.","volume":"35","author":"Taha","year":"2017","journal-title":"Vaccine"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/INF.0000000000001399","article-title":"Neisseria meningitidis serogroup B Vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains.","volume":"36","author":"Harris","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1016\/j.vaccine.2017.07.056","article-title":"Emerging clinical experience with vaccines against group B meningococcal disease.","volume":"36","author":"Wilkins","year":"2018","journal-title":"Vaccine"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.vaccine.2018.12.061","article-title":"Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide.","volume":"37","author":"Muzzi","year":"2019","journal-title":"Vaccine"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/21645515.2018.1537756","article-title":"Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.","volume":"15","author":"Biolchi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R27-20250615","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cid\/cit243","article-title":"Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States.","volume":"57","author":"Mandal","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.38.9.3323-3328.2000","article-title":"Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.","volume":"38","author":"Tondella","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R29-20250615","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10096-013-1897-6","article-title":"Meningococcal carriage during a clonal meningococcal B outbreak in France.","volume":"32","author":"Delbos","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R31-20250615","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales.","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R32-20250615","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study.","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"R33-20250615","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"R34-20250615","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"R35-20250615","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity.","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"R36-20250615","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R37-20250615","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:05:44Z","timestamp":1750003544000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002957","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2020,10,13]]}}}